Lv21
112 积分 2023-03-21 加入
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
6小时前
已完结
An Update on Patent issues regarding Antibody Drug Conjugates
12天前
已完结
Dual-payload ADCs move into first oncology clinical trials
13天前
已完结
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
13天前
已完结
GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab
19天前
已完结
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
1个月前
已完结
Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma
1个月前
已完结
Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy
2个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
2个月前
已完结
The complex patent situation regarding antibody Fc engineering
2个月前
已完结
皖公网安备34019202002308
